Nelonicline citrate (ABT-126) is a selective α7 nicotinic acetylcholine receptor agonist with high binding affinity (Ki = 12.3 nM). It is a research tool used in preclinical studies for cognitive disorders, including investigations for schizophrenia and Alzheimer's disease.